Background: Patients with diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) 3 are at higher risk for relapse after a complete response (CR) to first-line rituximab-based chemotherapy (R-chemo). Everolimus has singleagent activity in lymphoma. PILLAR-2 aimed to improve disease-free survival (DFS) with 1 year of adjuvant everolimus.
Introduction
Diffuse large B-cell lymphoma (DLBCL), the most common lymphoma in adults, is typically treated with the anti-CD20 antibody rituximab combined with the CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy regimen (R-CHOP) [1] . Patients with an International Prognostic Index (IPI) score 3 are at higher risk of relapse than patients with IPI <3 [2] . Adjuvant therapy is one strategy to reduce the relapse risk in patients who achieved a CR after first-line R-CHOP. Previous studies using rituximab or enzastaurin maintenance failed to show improved outcomes of patients who had responded to first-line R-CHOP [3] [4] [5] .
Studies have demonstrated that the mammalian target of rapamycin (mTOR) pathway is a relevant target in DLBCL, and inhibition of the mTOR pathway induces G1-cell cycle arrest [6] . Results of a phase II study showed that everolimus was safe and had single-agent activity in patients with relapsed DLBCL (30% overall response rate) [7] . We hypothesized that R-CHOP therapy inadequately targets the PI3K/mTOR pathway and that everolimus adjuvant therapy would reduce relapse risk in patients achieving CR after R-CHOP. We designed the PILLAR-2 study to evaluate adjuvant everolimus in patients with high risk (IPI 3) DLBCL who had achieved a positron emission tomography/computed tomography (PET/CT)-confirmed CR to first-line rituximab-based chemotherapy (R-chemo).
Methods Study design and patients
PILLAR-2 was a phase III placebo-controlled study (NCT00790036). Adult patients (aged 18 years) with histologically confirmed stage II bulky disease or stage III/IV DLBCL at initial diagnosis with a CR based on PET scan (within 4 weeks of study drug start; per central review) after first-line R-chemo, and who were high risk according to IPI (IPI 3-5 at diagnosis), were enrolled in this study. Cell of origin (COO) classification of germinal center B-cell (GCB) and non-GCB tumors was determined through immunohistochemistry (IHC), and evaluated per central review using the modified Choi criteria [8] . Eligible patients were randomized (1 : 1) to everolimus 10 mg/day or placebo for 1 year and stratified by first-line R-chemo (R-CHOP or R-EPOCH) (supplementary Figure S1 , available at Annals of Oncology online). Dose reduction to 5 mg/day and then 5 mg/every other day was permitted to manage toxicity. Patients were required to initiate study drug 6-14 weeks after the end of R-chemo. Treatment duration was 12 months (i.e. 13 cycles, where 1 cycle ¼ 28 days) or until disease relapse, unacceptable toxicity, or death. The study was approved by local institutional review boards and conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. All patients provided written informed consent.
CR was defined as a negative PET scan (Deauville 1-3) and disappearance of any disease-related symptoms following five to eight cycles of first-line R-chemo [9] . High risk was defined as an IPI of 3-5, determined according to the criteria of Sehn et al. [2] . Patients were excluded if there was evidence of 18 F-FDG-avid disease [according to the revised International Workshop Response Criteria (IWRC) [9] ] after completion of first-line R-chemo or history of systemic therapy with an mTOR inhibitor.
End points and assessments
The primary end point was DFS, defined as the time from randomization to first documented relapse of disease or death due to any cause, by local assessment per the revised IWRC [9] . Secondary end points were overall survival (OS) and lymphoma-specific survival (LSS), defined as the time from randomization to death due to any cause (OS) and death due to lymphoma (LSS). The predefined data cutoff date for the primary end point was 31 December 2015, allowing for 2 years of follow-up after last patient randomized. Patients were assessed for disease relapse using the revised IWRC [9] at 12-week intervals for the first 2 years, at 24-week intervals during years 3 and 4, and annually thereafter until a confirmed DLBCL relapse or until the final DFS analysis. All patients were to have an end-of-treatment visit within 7 days of their last dose of study drug, and a post-treatment discontinuation visit for safety evaluations 28 days later. Disease assessments were carried out using CT with contrast or magnetic resonance imaging if CT was not possible and/or biopsy. Adverse events (AEs) were recorded throughout the study. The cut-off date for the final OS analysis was 15 June 2016.
Statistical analysis plan
Efficacy analyses were conducted on all randomized patients. Safety analyses were carried out on patients who received at least one dose of the study drug and had at least one post-baseline safety assessment. Adverse event severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0.
Assuming a hazard ratio (HR) of 0.70 (corresponding to 2-year DFS rate of 65% for placebo and 74% for everolimus), a total of 279 DFS events were originally required with 727 patients to be randomized. A group sequential design with two interim analyses at 35% and 70% information fraction of DFS events was used with a cumulative type I error of one-sided a ¼ 0.025 and a cumulative power of 80%. As a result of a slow-pooled (blinded) DFS event rate, the protocol was revised to conduct the primary analysis at a fixed cut-off date (31 December 2015). Further details are provided in the supplementary Appendix, available at Annals of Oncology online.
Time-to-event estimates were calculated using the Kaplan-Meier method and HRs (everolimus versus placebo) with 95% confidence intervals (CI) estimated using the Cox proportional hazards model with treatment as the only covariate. In the primary analysis, a one-sided log-rank test was used to compare DFS between treatment arms. In addition, a Cox proportional hazards model adjusting the treatment effect on prespecified key potential prognostic factors [i.e. IPI (3 versus 4 þ 5), tumor COO (GCB, non-GCB, other)] was used to estimate covariate-adjusted HR and 95% CI of treatment effect on DFS and OS. In addition, prespecified exploratory analyses of DFS and OS in these patient subgroups and race (white, Asian, other) were conducted although the primary end point was not met. These results were considered exploratory and hypothesis-generating.
Results

Patients
Between August 2009 and December 2013, 742 patients were enrolled ( Figure 1 ) and randomly assigned to everolimus or placebo. In the everolimus and placebo arms, 48% and 67% of patients, respectively, completed study treatment per protocol. The main reasons for treatment discontinuation were AEs (30%, everolimus; 12%, placebo) and disease relapse (6%, everolimus; 13%, placebo).
Baseline characteristics were generally balanced between treatment arms (Table 1 ) except for sex, where more males were randomly assigned to the placebo arm (55%) than the everolimus arm (45%). IHC COO analysis showed that 47% of patients had non-GCB COO subtype, 36% of patients had GCB subtype, and 17% of patients had either non-classified or missing tumor samples.
Efficacy outcomes
Median duration of follow-up was 50.4 months (range 24.0-76.9). At the primary analysis, DFS events had been reported in 23% of patients in the everolimus arm and 27% of patients in the placebo arm, which included relapses (20% and 24%, respectively) and deaths (3% in each arm). DFS did not differ significantly between treatment arms (HR 0.92; 95% CI 0.69-1.22; log-rank P ¼ 0.276) (Figure 2A ). The 2-year DFS rate was 77.8% (95% CI 72.7-82.1) in the everolimus arm and 77.0% (95% CI 72.1-81.1) in the placebo arm. Estimated HR of treatment effect for DFS adjusted for key prognostic factors was consistent with the unadjusted primary analysis (HR 0.90; 95% CI: 0.67-1.22). No formal statistical testing of the key secondary end point of OS was undertaken, given that the primary end point of DFS was not met.
At primary analysis, 46 patients in the everolimus and 64 in the placebo groups had died. There was no statistically significant improvement in OS with everolimus in both primary and final OS analyses [primary, HR 0.75; 95% CI 0.51-1.10 ( Figure 2B 
Safety
Median duration of treatment was 48.4 weeks (range 0-66) in the everolimus arm and 52.0 weeks (range 0-63) in the placebo arm. The actual mean dose intensity (6standard deviation) was 7.9 mg/day (2.39) in the everolimus arm and 9.4 mg/day (1.35) in the placebo arm. The dose was reduced or interrupted at least once in 67% of patients in the everolimus arm and in 43% of patients in the placebo arm. Among the 48% of patients who completed everolimus per protocol, the median relative dose intensity was 85% (range 23-147). The two most frequent causes of dose reduction or interruption were AEs (47%, everolimus; Figure 1 . CONSORT diagram. A total of 1007 patients were screened and 742 were randomized, 372 to the everolimus group and 370 to the placebo group. Ten patients did not receive treatment because of administrative problems, protocol deviation, or withdrawn consent, and an additional 306 discontinued treatment due to various reasons.
16%, placebo), and laboratory test abnormality (24%, everolimus; 15%, placebo). The three most commonly reported AEs were stomatitis, diarrhea, and neutropenia with everolimus and neutropenia, fatigue, and diarrhea with placebo (supplementary Table S1 , available at Annals of Oncology online). Treatmentrelated grade 3 or 4 AEs were reported in 54% of patients in the everolimus arm and 25% of patients in the placebo arm. Adverse events (regardless of relationship to treatment and including abnormal laboratory values) led to treatment discontinuation for 31% of patients in the everolimus arm and 13% of patients in the placebo arm. The rate of discontinuation due to pneumonitis was 2% for patients treated with everolimus. Five patients in the everolimus arm (1.4%) and two patients in the placebo arm (0.5%) died during the study treatment or within 28 days of treatment discontinuation. Causes of death in the everolimus arm were congestive heart failure, intracranial hemorrhage, hepatitis B virus, septic shock, and an unknown cause. Two deaths in the everolimus arm and one death in the placebo arm were caused by AEs suspected to be drug-related. Of the deaths in the everolimus arm that were suspected to be drugrelated, one was attributed to hepatitis B virus reactivation and one was of unknown cause, and thus was categorized as drugrelated by default.
Discussion
Despite the strong rationale for targeting the PI3K/mTOR pathway with everolimus in patients with high-risk DLBCL, results of the current study failed to demonstrate a significant improvement in DFS with adjuvant everolimus in this patient population who were in a PET negative remission after R-chemo. We did observe a separation of the Kaplan-Meier curves for DFS during the first 18 months, although HRs (95% CIs) and Kaplan-Meier estimates of OS and LSS indicated that everolimus did not significantly improve either outcome. On-treatment benefit of everolimus could potentially have been sustained with treatment beyond 1 year; however, tolerability of AEs and motivation for staying on a therapy in the adjuvant setting was generally low. In our study, only 48% of patients in the everolimus arm and 67% of patients in the placebo arm actually completed study treatment per protocol design, and AEs were the primary reason for discontinuation (30%, everolimus; 12%, placebo). The issue of low tolerability of AEs was highlighted in our study by the high percentage of patients in the placebo arm who experienced allgrade AEs (92%) and grade 3 or 4 AEs (42%). For comparison, the rates of all-grade AEs and grade 3 or 4 AEs were 99% and 65%, respectively, in the everolimus arm. Managing AEs through more dose reductions may have improved tolerability of adjuvant everolimus and increased patient compliance.
Although the results should be considered exploratory and hypothesis generating, prespecified subgroup analyses in certain patient subgroups are reported. These subgroups had substantial numbers of patients, and the ones who appeared to potentially benefit from everolimus had an IPI prognostic factor of 4 þ 5, were male, were aged <65 years, or were Asian. As patients with higher IPI score (4 þ 5 versus 3) and male (versus female) have a higher risk of relapse, these patients in particular may benefit from adjuvant everolimus. In the current study, we report DFS HRs for everolimus versus placebo of 0.68 (95% CI 0.45-1.05) for male patients and 1.24 (95% CI 0.82-1.87) for female patients.
Certainly, further analysis would be necessary to determine whether a beneficial difference by subgroup exists. To put our results into context, two studies of rituximab maintenance therapy versus observation in DLBCL also evaluated survival outcomes in male patients, and results of both studies showed that male patients derived more benefit from treatment [10, 11] . Taken together, these results are in line with those of our exploratory analyses.
The AE profile observed for everolimus in the current study was generally consistent with the known safety profile of everolimus in other cancers [12] [13] [14] [15] , and no unexpected safety signals were identified. Stomatitis, a known class effect of mTOR inhibitors, was the most common AE in the everolimus arm. 372  329  299  292  271  228  183  157  122  80  45  25  2   370  340  321  303  291  242  189  160  126  85  46  18 (A) Disease-free survival (DFS) and overall survival (B) by treatment arm, analyzed using Kaplan-Meier curves. The primary analysis cutoff date was 31 December 2015. For DFS, P value (one-sided) was obtained from the log-rank test and the hazard ratio (HR) was obtained using unadjusted Cox proportional hazard model and defined as everolimus versus placebo. For OS, the HR was obtained using unadjusted Cox proportional hazard model and defined as everolimus versus placebo. CI, confidence interval.
Noninfectious pneumonitis, also a class effect of mTOR inhibitors, led to treatment discontinuation in seven patients in the everolimus arm (2%) and two patients in the placebo arm (0.5%). On-treatment deaths occurred more frequently in the everolimus arm than in the placebo arm (five versus two deaths); among the five patients in the everolimus arm who died, two of the deaths [the one that resulted from hepatitis B virus reactivation and the one reported as unknown (by default)] were suspected to be related to treatment. The patient with HBV reactivation had reactive HBsAg and HBcAb and nonreactive HBsAb at screening, an HBV-DNA level <29 on the first day of treatment, and was receiving prophylactic entecavir. No adjuvant or maintenance strategy for patients with DLBCL has to date been successful at prolonging OS when applied to those who have already achieved a PET/CT CR. Recently, enzastaurin, a selective protein kinase C beta inhibitor, also failed to Figure 3 . Forest plots of disease-free survival (A) and overall survival (B) by patient subgroups. Exploratory analysis was carried out for International Prognosis Index (IPI) (3 or 4 þ 5), sex (male or female), age (<65 or 65 years), cell of origin by immunohistochemistry (GCB, non-GCB, or other), and race (white, Asian, or other). The primary analysis cut-off date was 31 December 2015. GCB, germinal center B-cell; CI, confidence interval.
show significant DFS benefit as an adjuvant therapy in patients with high-risk DLBCL who had achieved CR after first-line R-CHOP therapy [5] . Autologous stem-cell transplant (ASCT) as adjuvant therapy has also been tested after CHOP or R-CHOP induction in a phase III trial (S9704), but did not produce a survival advantage [16] . Recently, Thieblemont et al. randomized patients who had achieved a CR by PET or a CR/PR by CT with standard R-CHOP to oral lenalidomide versus placebo for 2 years [17] . This trial did indeed show a statistically significant benefit in favor of lenalidoimide maintenance with respect to PFS; however, there was no difference in OS.
Given the generally negative results of these trials using adjuvant therapy in DLBCL, future trial designs should focus on combining novel agents with the R-CHOP. Leonard et al. recently reported no improvement with the addition of the proteasome inhibitor bortezomib to standard R-CHOP compared with R-CHOP alone in the upfront setting [18] . A recent phase I feasibility study, also designed in 2008, evaluated first-line everolimus combined with R-CHOP in patients with untreated DLBCL (stages 2-4) (N ¼ 24) [19] . 96% of patients achieved an overall response and had PET-confirmed CR; there have been no DLBCL relapses to date. Other studies have also evaluated first-line R-CHOP combined with other agents. For example, patients who received first-line R-CHOP combined with either lenalidomide or ibrutinib achieved CR rates ranging from 86% to 72%, respectively [20, 21] . Taken together, results of these studies highlight the need for more effective first-line therapies that improve survival for patients with DLBCL.
In summary, adjuvant everolimus did not improve DFS in patients with high-risk (IPI 3) DLBCL who achieved a PET/CTconfirmed CR following R-chemo. Preliminary results with everolimus combined with R-CHOP in the upfront setting [22] warrant further investigation in DLBCL. In addition, new agents targeting the PI3K/mTOR pathway should be tested as upfront rather than adjuvant therapy.
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